Pridopidine not checked
Prilenia · ACR16 · TV7820
FollowEvery change as it happens, and a Monday email
Trials
3 active
11 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Amyotrophic Lateral Sclerosis, Huntington Disease
- Main trialPhase 3
- “The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is: Does pridopidine slow disease progression of ALS? Researchers will compare pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works to treat ALS. Participants will: Take pridopidine or a placebo by mouth every day for 48 weeks. Afterwards, all participants will take pridopidine for another 48 weeks. Visit the clinic once…”In the company’s words, NCT07322003 on ClinicalTrials.gov
- Other names
- ACR16 · TV7820
Other drugs for Amyotrophic Lateral Sclerosis
Coming up2
- Mar 2028Phase 3 trial completes · ClinicalTrials.gov
- Jun 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Mar 2028 | Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS | |
| Phase 3Recruiting | Jun 2028 | Pridopidine Phase 3 Study in Huntington's Disease | |
| Phase 3Completed | 14 Jun 2010 | A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease | |
| Phase 3Completed | 14 Mar 2023 | PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD | |
| Phase 2Completed | 26 Jul 2010 | A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease | |
| Phase 2Completed | 16 Dec 2015 | A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease | |
| Phase 2Completed | 5 Jan 2018 | Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease | |
| Phase 2Terminated | 12 Jan 2018 | A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease | |
| Phase 2Terminated | 22 Jul 2020 | A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease | |
| Phase 1Completed | 9 Feb 2018 | A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease | |
| Phase 3Authorised | not given | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Amyotrophic Lateral Sclerosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026